no weight loss on compounded semaglutide NYC FDA Warns on Certain Forms
Description
S.GiradaS
Wegovy functions similarly to compounded semaglutide but it has been examined under different clinical trials focusing more on its effect on weight loss rather than glycemic control
doi: 10.1210/endocr/bqaa246
Consistent with the binding affinities acquired by SPR, GLP-1 LX exhibited the weakest binding and dissociated from the column first at pH 6.3, followed by GLP-1 WT at pH 6.7 and Tanzeum at pH 6.9 (Fig
Effects on weight SGLT2-I on average result in a small reduction in weight, possibly due to reduction in glucose reabsorption
The text references a GLP-1 prescription
